PARP Inhibitor Maintenance in Newly Diagnosed Ovarian Cancer: Key Questions, Answers, and Insights 

Gynecologic Cancer Education: PARP Inhibitor TherapyПодробнее

PARP Inhibitors: New Insights & Future of Ovarian Cancer TreatmentПодробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее

Targeted Therapy in Newly Diagnosed Advanced Ovarian CancerПодробнее

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian CancerПодробнее

Webinar: PARP Inhibitors and Ovarian CancerПодробнее

Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion DiagnosticsПодробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее

Comment on SOLO1 for advanced ovarian cancerПодробнее

Enhancing Personalized Medicine in Ovarian Cancer: Advances in PARP Inhibition and Novel ModalitiesПодробнее

PARP Inhibitors with Johnathan LedermanПодробнее

Ovarian Cancer: PARP Inhibitors and Beyond (Webinar) May 8th World Ovarian Cancer DayПодробнее

Managed Care Implications of the Expanding Role of PARP Inhibitors in OncologyПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancerПодробнее

A Webinar on PARP Inhibitors in Epithelial Ovarian CancerПодробнее